Ambler Brook Backs Claimify in Strategic Healthcare Tech Push

Ambler Brook, a Boston-based private equity firm specializing in healthcare and business services, has announced a strategic growth investment in Claimify, a rapidly expanding platform that automates insurance verification and claims processing for medical practices across the United States. The investment, announced February 24, 2026, marks Ambler Brook's latest move to capitalize on the accelerating digital transformation sweeping through healthcare administration.

While financial terms were not disclosed, the transaction represents a significant validation of Claimify's technology platform and growth trajectory in the fragmented but critical revenue cycle management sector. The deal comes as healthcare providers increasingly seek automated solutions to navigate the complexities of insurance billing, which costs the U.S. healthcare system an estimated $496 billion annually in administrative expenses.

Claimify operates at the intersection of two powerful healthcare trends: administrative burden reduction and digital transformation. The company's platform automates what has traditionally been a labor-intensive process—verifying patient insurance eligibility and submitting claims to payers. For medical practices, this automation translates directly to faster reimbursement, reduced claim denials, and lower administrative costs.

The addressable market is substantial. According to the Medical Group Management Association, the average medical practice spends 14% of total revenue on billing and collections activities. With approximately 1.1 million practicing physicians in the United States and average practice revenues exceeding $2 million annually, the revenue cycle management software market is projected to reach $38.4 billion by 2028, growing at a compound annual rate of 12.3%.

Claimify's competitive advantage lies in its ability to integrate with existing electronic health record (EHR) systems while providing real-time insurance verification and intelligent claims scrubbing. The platform reportedly serves thousands of healthcare providers, from small independent practices to multi-location group practices across specialties including orthopedics, cardiology, primary care, and behavioral health.

For Ambler Brook, the Claimify investment aligns squarely with the firm's established focus on growth-stage companies in healthcare technology and services. The firm, which manages approximately $800 million in committed capital, has built a track record of partnering with founder-led businesses to accelerate growth while preserving entrepreneurial culture.

The investment fits a broader pattern in healthcare private equity. According to Pitchbook data, healthcare IT deals in the growth equity and venture growth stage attracted $12.3 billion in 2025, up from $9.8 billion in 2024. Within that category, revenue cycle management platforms have emerged as particularly attractive targets, combining recurring revenue models with measurable returns on investment for customers.

Ambler Brook's approach typically involves providing not just capital but operational support to help portfolio companies professionalize operations, expand sales and marketing capabilities, and pursue strategic acquisitions. The firm has previously invested in healthcare services companies including diagnostic laboratories, specialty pharmacies, and healthcare staffing businesses.

According to the announcement, Claimify will deploy the new capital across several strategic priorities designed to accelerate market penetration and product development.

The company plans significant expansion of its go-to-market teams. This includes hiring additional sales representatives focused on mid-sized medical groups (10-50 providers), a segment that has historically been underserved by legacy revenue cycle vendors but increasingly seeks sophisticated automation tools. The company will also invest in marketing infrastructure to build brand awareness and generate qualified leads through digital channels.

Technology investment will focus on enhancing Claimify's artificial intelligence and machine learning capabilities, particularly in predictive denial management. By analyzing historical claims data, the platform aims to identify patterns that lead to denials before claims are submitted, allowing practices to correct issues proactively. The company is also developing enhanced analytics dashboards that provide practice administrators with actionable insights into revenue cycle performance.

Claimify plans to deepen integrations with leading EHR platforms including Epic, Cerner Oracle Health, and Athenahealth. Seamless EHR integration is critical for adoption, as medical practices are reluctant to adopt solutions requiring duplicate data entry or complex workflows. The company is also exploring partnerships with practice management consultants and healthcare IT value-added resellers to expand distribution channels.

Recognizing that retention and expansion revenue drive software-as-a-service (SaaS) economics, Claimify will build out dedicated customer success teams. These teams will work with existing clients to maximize platform adoption, identify opportunities for expanded use cases, and ensure customers achieve targeted ROI metrics. In the competitive RCM software market, net revenue retention rates above 110% have become table stakes for premium valuations.

The revenue cycle management software market has undergone significant consolidation in recent years, creating a landscape of established enterprise players and emerging disruptors. Legacy vendors like R1 RCM (formerly Accretive Health), Conifer Health Solutions, and Optum360 dominate the hospital and large health system segment with comprehensive, but often complex and expensive, solutions.

In the mid-market and physician practice segment where Claimify competes, the landscape includes a mix of established players like AdvancedMD and Kareo (now part of Tebra), as well as newer entrants like Sift Healthcare and Rivet. Each competitor brings different strengths—some focus on end-to-end practice management, others on analytics, and still others on specific revenue cycle functions like patient payment collection or denial management.

Claimify's positioning appears focused on providing best-of-breed automation for specific revenue cycle functions—insurance verification and claims submission—rather than attempting to replace entire practice management systems. This approach allows the company to integrate with existing technology stacks while delivering rapid ROI on a narrowly defined problem. It's a strategy that has worked well for point solution providers in other healthcare IT categories.

The Claimify investment occurs against a complex macroeconomic backdrop for healthcare services. Physician practices continue to face margin pressure from multiple directions: rising labor costs (particularly for clinical and administrative staff), increasing regulatory compliance burdens, and ongoing reimbursement pressure from both government and commercial payers.

These pressures create urgency for automation solutions that deliver measurable cost savings. A 2025 survey by the American Medical Association found that 78% of practice administrators identified revenue cycle efficiency as a top-three technology investment priority, up from 62% in 2023. The same survey found that practices using automated eligibility verification and claims scrubbing reported 23% lower administrative costs per patient visit compared to practices relying primarily on manual processes.

From a private equity perspective, healthcare IT investments have maintained appeal despite broader technology market volatility. According to Bain & Company's Global Healthcare Private Equity Report, healthcare IT companies in PE portfolios achieved median revenue growth of 18% in 2025, compared to 12% for software companies overall. Healthcare IT also demonstrated superior retention characteristics, with median net revenue retention of 112% compared to 105% for broader B2B SaaS.

While the announcement does not detail specific transaction terms, growth equity investments in profitable healthcare IT companies typically involve several standard elements. Based on comparable transactions and market norms, we can infer likely deal characteristics.

First, the investment likely represents a minority stake, allowing Claimify's founders and management team to maintain control while providing meaningful liquidity and capital for growth initiatives. Growth equity firms typically acquire 20-40% ownership in such transactions, with valuations based on forward revenue multiples ranging from 6-12x depending on growth rates, profitability, and market positioning.

Second, the deal probably includes structured governance rights allowing Ambler Brook to appoint board members and participate in strategic decisions around M&A, significant capital expenditures, and leadership changes. These provisions protect the investor's capital while preserving operational autonomy for management.

Third, the investment likely incorporates performance-based earnouts or ratchets that allow management to earn additional equity if the company achieves specified growth or profitability targets. These alignment mechanisms are standard in growth equity transactions and help bridge valuation gaps between investors and founders.

For Claimify, the partnership with Ambler Brook provides the resources and expertise to pursue an ambitious growth agenda. The company enters a critical scaling phase where operational execution will determine long-term success. Key performance indicators will include customer acquisition efficiency (measured by customer acquisition cost to lifetime value ratios), product adoption rates, net revenue retention, and gross margin expansion.

The company will also face strategic decisions around potential acquisitions. The revenue cycle management space remains fragmented, with numerous small players serving niche specialties or geographic markets. Claimify may pursue tuck-in acquisitions to accelerate market share gains, acquire complementary technologies, or enter adjacent market segments like patient payment collection or denial management services.

For Ambler Brook, success will be measured by the firm's ability to help Claimify achieve the scale and profitability characteristics that support a successful exit—whether through sale to a strategic acquirer, secondary sale to a larger private equity firm, or eventual public markets transaction. Based on typical hold periods for growth equity investments, that exit likely sits 4-6 years in the future.

The transaction signals continued private equity interest in healthcare technology businesses that serve the provider market. Unlike consumer health or payer-focused technologies, provider-focused solutions benefit from defined buyers (medical practices), measurable ROI, and recurring revenue models based on transaction volumes or subscription fees.

The investment also highlights the ongoing fragmentation in healthcare IT. Despite decades of consolidation, no single vendor dominates the mid-market physician practice segment. This fragmentation creates opportunities for well-positioned companies with superior technology and go-to-market execution to capture meaningful market share.

Finally, the deal underscores the importance of administrative burden reduction in healthcare delivery. As physician practices face mounting economic pressures, technologies that reduce costs while improving collections will remain highly attractive investment targets. The companies that successfully combine automation with user-friendly design and measurable outcomes will likely command premium valuations and attract continued capital deployment.

As healthcare continues its digital transformation, revenue cycle automation represents one of the clearest applications of technology to solve persistent industry challenges. Ambler Brook's investment in Claimify places a significant bet on this thesis—and on the company's ability to execute against a substantial market opportunity. The months and years ahead will reveal whether that bet pays off for both the investors and the healthcare providers the platform serves.